Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Sage Therapeutics, Inc (SAGE)

Pharmaceutical Preparations

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

215 FIRST STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/18/2014

Market Cap

494,508,240

Shares Outstanding

60,030,000

Weighted SO

60,032,854

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

APLS --.--%

TERN --.--%

DAWN --.--%

BPMC --.--%

CERE --.--%

MRTX --.--%

AMLX --.--%

RLAY --.--%

STOK --.--%

Beta

0.9000

Last Div

0.0000

Range

7.7-28.26

Chg

-0.2000

Avg Vol

1184493

Mkt Cap

494508240

Exch

NASDAQ

Country

US

Phone

617 299 8380

DCF Diff

23.3156

DCF

-0.0456

Div Yield

0.0000

P/S

5.0852

EV Multiple

-0.9530

P/FV

0.7808

Div Yield %

0.0000

P/E

-1.1003

PEG

-0.0360

Payout

0.0000

Current Ratio

9.9476

Quick Ratio

9.9476

Cash Ratio

1.4662

DSO

51.5836

DIO

0.0000

Op Cycle

51.5836

DPO

717.3938

CCC

-665.8102

Gross Margin

0.9547

Op Margin

-4.9597

Pretax Margin

-4.5830

Net Margin

-4.5830

Eff Tax Rate

-0.0313

ROA

-0.6393

ROE

-0.6043

ROCE

-0.7679

NI/EBT

1.0000

EBT/EBIT

0.9241

EBIT/Rev

-4.9597

Debt Ratio

0.0020

D/E

0.0022

LT Debt/Cap

0.0000

Total Debt/Cap

0.0022

Int Coverage

-55.8090

CF/Debt

-264.8150

Equity Multi

1.1099

Rec Turnover

7.0759

Pay Turnover

0.5088

Inv Turnover

0.0000

FA Turnover

38.9912

Asset Turnover

0.1395

OCF/Share

-6.1722

FCF/Share

-6.1758

Cash/Share

10.7060

OCF/Sales

-3.8424

FCF/OCF

1.0006

CF Coverage

-264.8150

ST Coverage

-264.8150

CapEx Coverage

-1729.8796

Div&CapEx Cov

-1729.8796

P/BV

0.7808

P/B

0.7808

P/S

5.0852

P/E

-1.1003

P/FCF

-1.3227

P/OCF

-1.3123

P/CF

-1.3123

PEG

-0.0360

P/S

5.0852

EV Multiple

-0.9530

P/FV

0.7808

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 05, 13:51 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders Benzinga Oct 25, 00:02 SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit GlobeNewswire Inc. Oct 24, 00:06 Sage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion Benzinga Oct 23, 03:05 SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit GlobeNewswire Inc. Oct 20, 01:45 SAGE DEADLINE: RLF, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 18, 00:42 ROSEN, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 12, 01:07 ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 03, 22:44 ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Sep 30, 01:08 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Sep 26, 23:26 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE Benzinga Sep 17, 22:37 Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) GlobeNewswire Inc. Sep 14, 13:36 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE Benzinga Sep 11, 23:55 INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors GlobeNewswire Inc. Aug 30, 05:45 SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights Benzinga Aug 29, 22:13 SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm Seeking Alpha Nov 20, 00:24 Buy These Stocks; Members Of The Most Hated Tech Sector The Motley Fool Nov 07, 18:02 Why Sage Therapeutics Stock Sank Today

Revenue Product Segmentation